Highlighting its commitment to cardiovascular and metabolic diseases, Pfizer has agreed to license AKCEA-ANGPTL3-LRx from Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals. The deal, worth potentially up to US$1.55 B, comes as Akcea faces challenges in commercialising its therapies Waylivra® (volanesorsen) for the treatment of familial chylomicronemia syndrome and Tegsedi® (inotersen) for hereditary transthyretin amyloidosis.